Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 4

Терапевтический потенциал флувоксамина для больных COVID-19
Е.Ю. Плотникова, М.Н. Синькова, Л.К. Исаков, А.С. Сухих

Список литературы

1. Figgitt DP, McClellan KJ. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 2000 Oct;60(4):925-54.
2. Sugimoto Y, Tagawa N, Kobayashi Y, Mitsui-Saito K, Hotta Y, Yamada J. Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetine. European Journal of Pharmacology 2012 Dec;696(1-3):96-100.
3. Dell’Osso B, Allen A, Hollander E. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy 2005 Dec;6(15):2727-40.
4. U.S. Food and Drug Administration. Highlights of prescribing information. Fluvoxamine maleate tablets for oral administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf Accessed 2022 Feb 25.
5. Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatric Disease and Treatment 2005 Dec;1(4):289-99.
6. Buchberger R, Wagner W. Fluvoxamine: safety profile in extensive post-marketing surveillance. Pharmacopsychiatry 2002 May;35(3):101-8.
7. Assimon MM, Brookhart MA, Flythe JE. Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. Journal of the American Society of Nephrology 2019 Apr;30(4):611-23.
8. van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics 1995;29(Suppl 1):1-9.
9. Wagner W, Vause EW. Fluvoxamine: a review of global drug-drug interaction data. Clinical Pharmacokinetics 1995;29(Suppl 1):26-31; discussion 31-2.
10. Medindia. Fluvoxamine trade names. Available from: https://www.medindia.net/drugs/trade-names/fluvoxamine.htm Accessed 2022 Feb 25.
11. Marčec R, Likić R. Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units? Croatian Medical Journal 2021 Feb;62(1):95-100.
12. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 2020 Dec;324(22):2292-300.
13. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infectious Diseases 2021 Feb;8(2):ofab050.
14. Reis G, dos Santos Moreiros Silva EA, dos Santos Medeiros Silva D, Thorlund K, Thabane L, Guyatt GH, Forrest JI, Glushchenko AV, Chernecki C, McKay P, Sprague S, Harari O, Ruton H, Rayner CR, Mills EJ. A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. Gates Open Research 2021 Aug;5:117.
15. NIH; U.S. Library of Medicine; ClinicalTrials.gov. Clinical trial for SARS-CoV-2 vaccine (COVID-19). Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-9&term=fluvoxamine&cntry=&state=&city=&dist Accessed 2022 Feb 25.
16. BJC HealthCare. COVID-19 adult treatment guidance. Updated January 15, 2021. Available from: https://covid19.bjc.org/Portals/0/PDF%20Documents/Clinical%20Resources/BJC_COVID-19_Treatment_Guidance_Final_1.pdf?ver=lk2wlZrR_T62_7WN0ac57A%3D%3D&__cf_chl_captcha_tk__=U3pw3h3226DNQ6DF3wfR5hbVKczRJN9cmiUWnvW4N6g-1639047840-0-gaNycGzNCOU Accessed 2022 Feb 25.
17. Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group. Therapeutic Management of Adult Patients with COVID-19. Available from: https://covid19-sciencetable.ca/wp-content/uploads/2021/12/Clinical-Practice-Guidelines_Update_20211222.pdf Accessed 2022 Feb 25.
18. Auwaerter PG. Johns Hopkins ABX Guide. Coronavirus COVID-19 (SARS-CoV-2). Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540747/all/Coronavirus_COVID_19__SARS_CoV_2_#9.0 Accessed 2022 Feb 25.
19. Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Molecular Psychiatry 2022; Jan7:1-10. doi: 10.1038/s41380-021-01432-3. Online ahead of print.
20. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annual Review of Medicine 2009;60:355-66.
21. Herr N, Bode C, Duerschmied D. The effects of serotonin in immune cells. Frontiers in Cardiovascular Medicine 2017 Jul;4:48.
22. Wan M, Ding L, Wang D, Han J, Gao P. Serotonin: a potent immune cell modulator in autoimmune diseases. Frontiers in Immunology 2020 Feb;11:186.
23. Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, Velasco-Velázquez MA, Garcés-Alvarez ME, Hurtado-Alvarado G, Quintero-Fabian S, Pavón L. Immunomodulatory effects mediated by serotonin. Journal of Immunology Research 2015;2015:354957.
24. Müller T, Dürk T, Blumenthal B, Grimm M, Cicko S, Panther E, Sorichter S, Herouy Y, Di Virgilio F, Ferrari D, Norgauer J, Idzko M. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009 Jul;4(7):e6453.
25. Vašíček O, Lojek A, Číž M. Serotonin and its metabolites reduce oxidative stress in murine RAW264.7 macrophages and prevent inflammation. Journal of Physiology and Biochemistry 2020 Feb;76(1):49-60.
26. Kubera M, Kenis G, Bosmans E, Scharpé S, Maes M. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology 2000 Jul;23(1):89-98.
27. Katoh N, Soga F, Nara T, Tamagawa-Mineoka R, Nin M, Kotani H, Masuda K, Kishimoto S. Effect of serotonin on the differentiation of human monocytes into dendritic cells. Clinical & Experimental Immunology 2006 Nov;146(2):354-61.
28. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. Journal of Immunology (Baltimore, Md.: 1950) 2002 Sep;169(5):2253-63.
29. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Médecine et Maladies Infectieuses 2020 Jun;50(4):382-3.
30. Ménard G, Turmel V, Bissonnette EY. Serotonin modulates the cytokine network in the lung: involvement of prostaglandin E2. Clinical & Experimental Immunology 2007 Nov;150(2):340-8.
31. Cadirci E, Halici Z, Bayir Y, Albayrak A, Karakus E, Polat B, Unal D, Atamanalp SS, Aksak S, Gundogdu C. Peripheral 5-HT7 receptors as a new target for prevention of lung injury and mortality in septic rats. Immunobiology 2013 Oct;218(10):1271-83.
32. Liu MW, Su MX, Wang YH, Wei W, Qin LF, Liu X, Tian ML, Qian CY. Effect of melilotus extract on lung injury by upregulating the expression of cannabinoid CB2 receptors in septic rats. BMC Complementary and Alternative Medicine 2014 Mar;14:94.
33. Kubera M, Maes M, Kenis G, Kim YK, Lasoń W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Research 2005 Apr;134(3):251-8.
34. Ayaz G, Halici Z, Albayrak A, Karakus E, Cadirci E. Evaluation of 5-HT7 receptor trafficking on in vivo and in vitro model of lipopolysaccharide (LPS)-induced inflammatory cell injury in rats and LPS-treated A549 cells. Biochemical Genetics 2017 Feb;55(1):34-47.
35. Mota CMD, Borges GS, Amorim MR, Carolino ROG, Batalhão ME, Anselmo-Franci JA, Carnio EC, Branco LGS. Central serotonin prevents hypotension and hypothermia and reduces plasma and spleen cytokine levels during systemic inflammation. Brain, Behavior, and Immunity 2019 Aug;80:255-65.
36. Saper CB, Romanovsky AA, Scammell TE. Neural circuitry engaged by prostaglandins during the sickness syndrome. Nature Neuroscience 2012 Jul;15(8):1088-95.
37. Pashaei Y. Drug repurposing of selective serotonin reuptake inhibitors: could these drugs help fight COVID-19 and save lives? Journal of Clinical Neuroscience 2021 Jun;88:163-72.
38. Glebov O. Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants. Frontiers in Pharmacology 2021 Dec;12:787261.
39. Esfahani NH, Rafiee L, Javanmard HS. Evaluation of the effect of antidepressant drug, fluvoxamine, on cyclooxygenase-2 protein expression in lipopolysaccharide-stimulated macrophages. Advanced Biomedical Research 2019 Jan;8:5.
40. Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proceedings of the National Academy of Sciences of the USA 1996 May;93(10):4885-90.
41. Yoshimura R, Katsuki A, Atake K, Hori H, Igata R, Konishi Y. Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder. Neuropsychiatric Disease Treatment 2017 Feb;13:437-41.
42. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet. Psychiatry 2021 Feb;8(2):130-40.
43. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. The European Respiratory Journal 2020 Oct;56(4):2003006.
44. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020 May;181(5):1036-45.e9.
45. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 2020 Mar;395(10229):1033-4.
46. Herold T, Jurinovic V, Arnreich C, Lipworth B, Hellmuth JC, von Bergwelt-Baildon M, Klein M, Weinberger T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. The Journal of Allergy and Clinical Immunology 2020 Jul;146(1):128-36.e4.
47. Laguna-Goya R, Utrero-Rico A, Talayero P, Lasa-Lazaro M, Ramierz-Fernandez A, Naranjo L, Segura-Tudela A, Cabrera-Marante O, de Frias ER, Garcia-Garcia R, Fernández-Ruiz M, Aguado JM, Martinez-Lopez J, Lopez EA, Catalan M, Serrano A, Paz-Artal E. IL-6-based mortality risk model for hospitalized patients with COVID-19. The Journal of Allergy and Clinical Immunology 2020 Oct;146(4):799-807.e9.
48. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in hospitalized patients with Covid-19. The New England Journal of Medicine 2021 Feb;384(8):693-704.
49. Sundstrom JB, Little DM, Villinger F, Ellis JE, Ansari AA. Signaling through toll-like receptors triggers HIV-1 replication in latently infected mast cells. Journal of Immunology (Baltimore, Md.: 1950) 2004 Apr;172(7):4391-401.
50. Fukuda M, Ushio H, Kawasaki J, Niyonsaba F, Takeuchi M, Baba T, Hiramatsu K, Okumura K, Ogawa H. Expression and functional characterization of retinoic acid-inducible gene-I-like receptors of mast cells in response to viral infection. Journal of Innate Immunity 2013;5(2):163-73.
51. Wang Z, Lai Y, Bernard JJ, Macleod DT, Cogen AL, Moss B, Di Nardo A. Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides. Journal of Immunology (Baltimore, Md.: 1950) 2012 Jan;188(1):345-57.
52. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors 2020 May;46(3):306-8.
53. Motta Junior JDS, Miggiolaro AFRDS, Nagashima S, de Paula CBV, Baena CP, Scharfstein J, de Noronha L. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Frontiers in Immunology 2020 Sep;11:574862.
54. Ferjan I, Erjavec F. Changes in histamine and serotonin secretion from rat peritoneal mast cells caused by antidepressants. Inflammation Research 1996 Mar;45(3):141-4.
55. Chen ZH, Xiao L, Chen JH, Luo HS, Wang GH, Huang YL, Wang XP. Effects of fluoxetine on mast cell morphology and protease-1 expression in gastric antrum in a rat model of depression. World Journal of Gastroenterology 2008 Dec;14(45):6993-8.
56. Härtter S, Wang X, Weigmann H, Friedberg T, Arand M, Oesch F, Hiemke C. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. Journal of Clinical Psychopharmacology 2001 Apr;21(2):167-74.
57. van den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 inflammasome dysregulated. Frontiers in Immunology 2020 Jul;11:1580.
58. Ratajczak MZ, Kucia M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells. Leukemia 2020 Jul;34(7):1726-9.
59. Ramlall V, Zucker J, Tatonetti N. Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv 2020 Oct 18. doi: 10.1101/2020.10.15.20213546. Preprint.
60. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thrombosis Research 2020 Oct;194:101-15.
61. Celada P, Dolera M, Alvarez E, Artigas F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. Journal of Affective Disorders 1992 Aug;25(4):243-9.
62. Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. International Journal of Antimicrobial Agents 2020 Aug;56(2):106044.
63. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004;18(5):269-84.
64. Hayashi T, Su TP. The sigma receptor: evolution of the concept in neuropsychopharmacology. Current Neuropharmacology 2005 Oct;3(4):267-80.
65. Hayashi T, Maurice T, Su TP. Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. Journal of Pharmacology and Experimental Therapeutics 2000 Jun;293(3):788-98.
66. Hayashi T, Su TP. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proceedings of the National Academy of Sciences of the USA 2001 Jan;98(2):491-6.
67. Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science (New York, N.Y.) 2020 Dec;370(6521):eabe9403.
68. Nicol GE, Karp JF, Reiersen AM, Zorumski CF, Lenze EJ. "What were you before the war?" Repurposing psychiatry during the COVID-19 pandemic. The Journal of Clinical Psychiatry 2020 Apr;81(3):20com13373.
69. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. European Journal of Pharmacology 2014 Mar;727:167-73.
70. Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, Gaultier A. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Science. Translational Medicine 2019 Feb;11(478):eaau5266.
71. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biological Psychiatry 2007 Oct;62(10):878-83.
72. Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. Journal of Pharmacological Sciences 2015 Jan;127(1):6-9.
73. Cobos EJ, Entrena JM, Nieto FR, Cendán CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Current Neuropharmacology 2008 Dec;6(4):344-66.
74. Hallifax D, Houston JB. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metabolism and Disposition 2007 Aug;35(8):1325-32.

References

1. Figgitt DP, McClellan KJ. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 2000 Oct;60(4):925-54.
2. Sugimoto Y, Tagawa N, Kobayashi Y, Mitsui-Saito K, Hotta Y, Yamada J. Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetine. European Journal of Pharmacology 2012 Dec;696(1-3):96-100.
3. Dell’Osso B, Allen A, Hollander E. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy 2005 Dec;6(15):2727-40.
4. U.S. Food and Drug Administration. Highlights of prescribing information. Fluvoxamine maleate tablets for oral administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf Accessed 2022 Feb 25.
5. Irons J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatric Disease and Treatment 2005 Dec;1(4):289-99.
6. Buchberger R, Wagner W. Fluvoxamine: safety profile in extensive post-marketing surveillance. Pharmacopsychiatry 2002 May;35(3):101-8.
7. Assimon MM, Brookhart MA, Flythe JE. Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. Journal of the American Society of Nephrology 2019 Apr;30(4):611-23.
8. van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics 1995;29(Suppl 1):1-9.
9. Wagner W, Vause EW. Fluvoxamine: a review of global drug-drug interaction data. Clinical Pharmacokinetics 1995;29(Suppl 1):26-31; discussion 31-2.
10. Medindia. Fluvoxamine trade names. Available from: https://www.medindia.net/drugs/trade-names/fluvoxamine.htm Accessed 2022 Feb 25.
11. Marčec R, Likić R. Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units? Croatian Medical Journal 2021 Feb;62(1):95-100.
12. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 2020 Dec;324(22):2292-300.
13. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infectious Diseases 2021 Feb;8(2):ofab050.
14. Reis G, dos Santos Moreiros Silva EA, dos Santos Medeiros Silva D, Thorlund K, Thabane L, Guyatt GH, Forrest JI, Glushchenko AV, Chernecki C, McKay P, Sprague S, Harari O, Ruton H, Rayner CR, Mills EJ. A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. Gates Open Research 2021 Aug;5:117.
15. NIH; U.S. Library of Medicine; ClinicalTrials.gov. Clinical trial for SARS-CoV-2 vaccine (COVID-19). Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-9&term=fluvoxamine&cntry=&state=&city=&dist Accessed 2022 Feb 25.
16. BJC HealthCare. COVID-19 adult treatment guidance. Updated January 15, 2021. Available from: https://covid19.bjc.org/Portals/0/PDF%20Documents/Clinical%20Resources/BJC_COVID-19_Treatment_Guidance_Final_1.pdf?ver=lk2wlZrR_T62_7WN0ac57A%3D%3D&__cf_chl_captcha_tk__=U3pw3h3226DNQ6DF3wfR5hbVKczRJN9cmiUWnvW4N6g-1639047840-0-gaNycGzNCOU Accessed 2022 Feb 25.
17. Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group. Therapeutic Management of Adult Patients with COVID-19. Available from: https://covid19-sciencetable.ca/wp-content/uploads/2021/12/Clinical-Practice-Guidelines_Update_20211222.pdf Accessed 2022 Feb 25.
18. Auwaerter PG. Johns Hopkins ABX Guide. Coronavirus COVID-19 (SARS-CoV-2). Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540747/all/Coronavirus_COVID_19__SARS_CoV_2_#9.0 Accessed 2022 Feb 25
19. Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Molecular psychiatry 2022; Jan7:1–10. doi: 10.1038/s41380-021-01432-3. Online ahead of print.
20. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annual Review of Medicine 2009;60:355-66.
21. Herr N, Bode C, Duerschmied D. The effects of serotonin in immune cells. Frontiers in Cardiovascular Medicine 2017 Jul;4:48.
22. Wan M, Ding L, Wang D, Han J, Gao P. Serotonin: a potent immune cell modulator in autoimmune diseases. Frontiers in Immunology 2020 Feb;11:186.
23. Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, Velasco-Velázquez MA, Garcés-Alvarez ME, Hurtado-Alvarado G, Quintero-Fabian S, Pavón L. Immunomodulatory effects mediated by serotonin. Journal of Immunology Research 2015;2015:354957.
24. Müller T, Dürk T, Blumenthal B, Grimm M, Cicko S, Panther E, Sorichter S, Herouy Y, Di Virgilio F, Ferrari D, Norgauer J, Idzko M. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009 Jul;4(7):e6453.
25. Vašíček O, Lojek A, Číž M. Serotonin and its metabolites reduce oxidative stress in murine RAW264.7 macrophages and prevent inflammation. Journal of Physiology and Biochemistry 2020 Feb;76(1):49-60.
26. Kubera M, Kenis G, Bosmans E, Scharpé S, Maes M. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology 2000 Jul;23(1):89-98.
27. Katoh N, Soga F, Nara T, Tamagawa-Mineoka R, Nin M, Kotani H, Masuda K, Kishimoto S. Effect of serotonin on the differentiation of human monocytes into dendritic cells. Clinical & Experimental Immunology 2006 Nov;146(2):354-61.
28. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. Journal of Immunology (Baltimore, Md.: 1950) 2002 Sep;169(5):2253-63.
29. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Médecine et Maladies Infectieuses 2020 Jun;50(4):382-3.
30. Ménard G, Turmel V, Bissonnette EY. Serotonin modulates the cytokine network in the lung: involvement of prostaglandin E2. Clinical & Experimental Immunology 2007 Nov;150(2):340-8.
31. Cadirci E, Halici Z, Bayir Y, Albayrak A, Karakus E, Polat B, Unal D, Atamanalp SS, Aksak S, Gundogdu C. Peripheral 5-HT7 receptors as a new target for prevention of lung injury and mortality in septic rats. Immunobiology 2013 Oct;218(10):1271-83.
32. Liu MW, Su MX, Wang YH, Wei W, Qin LF, Liu X, Tian ML, Qian CY. Effect of melilotus extract on lung injury by upregulating the expression of cannabinoid CB2 receptors in septic rats. BMC Complementary and Alternative Medicine 2014 Mar;14:94.
33. Kubera M, Maes M, Kenis G, Kim YK, Lasoń W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Research 2005 Apr;134(3):251-8.
34. Ayaz G, Halici Z, Albayrak A, Karakus E, Cadirci E. Evaluation of 5-HT7 receptor trafficking on in vivo and in vitro model of lipopolysaccharide (LPS)-induced inflammatory cell injury in rats and LPS-treated A549 cells. Biochemical Genetics 2017 Feb;55(1):34-47.
35. Mota CMD, Borges GS, Amorim MR, Carolino ROG, Batalhão ME, Anselmo-Franci JA, Carnio EC, Branco LGS. Central serotonin prevents hypotension and hypothermia and reduces plasma and spleen cytokine levels during systemic inflammation. Brain, Behavior, and Immunity 2019 Aug;80:255-65.
36. Saper CB, Romanovsky AA, Scammell TE. Neural circuitry engaged by prostaglandins during the sickness syndrome. Nature Neuroscience 2012 Jul;15(8):1088-95.
37. Pashaei Y. Drug repurposing of selective serotonin reuptake inhibitors: could these drugs help fight COVID-19 and save lives? Journal of Clinical Neuroscience 2021 Jun;88:163-72.
38. Glebov O. Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants. Frontiers in Pharmacology 2021 Dec;12:787261.
39. Esfahani NH, Rafiee L, Javanmard HS. Evaluation of the effect of antidepressant drug, fluvoxamine, on cyclooxygenase-2 protein expression in lipopolysaccharide-stimulated macrophages. Advanced Biomedical Research 2019 Jan;8:5.
40. Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proceedings of the National Academy of Sciences of the USA 1996 May;93(10):4885-90.
41. Yoshimura R, Katsuki A, Atake K, Hori H, Igata R, Konishi Y. Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder. Neuropsychiatric Disease Treatment 2017 Feb;13:437-41.
42. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet. Psychiatry 2021 Feb;8(2):130-40.
43. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. The European Respiratory Journal 2020 Oct;56(4):2003006.
44. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020 May;181(5):1036-45.e9.
45. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 2020 Mar;395(10229):1033-4.
46. Herold T, Jurinovic V, Arnreich C, Lipworth B, Hellmuth JC, von Bergwelt-Baildon M, Klein M, Weinberger T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. The Journal of Allergy and Clinical Immunology 2020 Jul;146(1):128-36.e4.
47. Laguna-Goya R, Utrero-Rico A, Talayero P, Lasa-Lazaro M, Ramierz-Fernandez A, Naranjo L, Segura-Tudela A, Cabrera-Marante O, de Frias ER, Garcia-Garcia R, Fernández-Ruiz M, Aguado JM, Martinez-Lopez J, Lopez EA, Catalan M, Serrano A, Paz-Artal E. IL-6-based mortality risk model for hospitalized patients with COVID-19. The Journal of Allergy and Clinical Immunology 2020 Oct;146(4):799-807.e9.
48. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in hospitalized patients with Covid-19. The New England Journal of Medicine 2021 Feb;384(8):693-704.
49. Sundstrom JB, Little DM, Villinger F, Ellis JE, Ansari AA. Signaling through toll-like receptors triggers HIV-1 replication in latently infected mast cells. Journal of Immunology (Baltimore, Md.: 1950) 2004 Apr;172(7):4391-401.
50. Fukuda M, Ushio H, Kawasaki J, Niyonsaba F, Takeuchi M, Baba T, Hiramatsu K, Okumura K, Ogawa H. Expression and functional characterization of retinoic acid-inducible gene-I-like receptors of mast cells in response to viral infection. Journal of Innate Immunity 2013;5(2):163-73.
51. Wang Z, Lai Y, Bernard JJ, Macleod DT, Cogen AL, Moss B, Di Nardo A. Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides. Journal of Immunology (Baltimore, Md.: 1950) 2012 Jan;188(1):345-57.
52. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors 2020 May;46(3):306-8.
53. Motta Junior JDS, Miggiolaro AFRDS, Nagashima S, de Paula CBV, Baena CP, Scharfstein J, de Noronha L. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Frontiers in Immunology 2020 Sep;11:574862.
54. Ferjan I, Erjavec F. Changes in histamine and serotonin secretion from rat peritoneal mast cells caused by antidepressants. Inflammation Research 1996 Mar;45(3):141-4.
55. Chen ZH, Xiao L, Chen JH, Luo HS, Wang GH, Huang YL, Wang XP. Effects of fluoxetine on mast cell morphology and protease-1 expression in gastric antrum in a rat model of depression. World Journal of Gastroenterology 2008 Dec;14(45):6993-8.
56. Härtter S, Wang X, Weigmann H, Friedberg T, Arand M, Oesch F, Hiemke C. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. Journal of Clinical Psychopharmacology 2001 Apr;21(2):167-74.
57. van den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 inflammasome dysregulated. Frontiers in Immunology 2020 Jun;11:1580.
58. Ratajczak MZ, Kucia M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells. Leukemia 2020 Jul;34(7):1726-9.
59. Ramlall V, Zucker J, Tatonetti N. Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv 2020 Oct 18. doi: 10.1101/2020.10.15.20213546. Preprint.
60. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thrombosis Research 2020 Oct;194:101-15.
61. Celada P, Dolera M, Alvarez E, Artigas F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. Journal of Affective Disorders 1992 Aug;25(4):243-9.
62. Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. International Journal of Antimicrobial Agents 2020 Aug;56(2):106044.
63. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004;18(5):269-84.
64. Hayashi T, Su TP. The sigma receptor: evolution of the concept in neuropsychopharmacology. Current Neuropharmacology 2005 Oct;3(4):267-80.
65. Hayashi T, Maurice T, Su TP. Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. Journal of Pharmacology and Experimental Therapeutics 2000 Jun;293(3):788-98.
66. Hayashi T, Su TP. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proceedings of the National Academy of Sciences of the USA 2001 Jan;98(2):491-6.
67. Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science (New York, N.Y.) 2020 Dec;370(6521):eabe9403.
68. Nicol GE, Karp JF, Reiersen AM, Zorumski CF, Lenze EJ. "What were you before the war?" Repurposing psychiatry during the COVID-19 pandemic. The Journal of Clinical Psychiatry 2020 Apr;81(3):20com13373.
69. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. European Journal of Pharmacology 2014 Mar;727:167-73.
70. Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, Gaultier A. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Science. Translational Medicine 2019 Feb;11(478):eaau5266.
71. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biological Psychiatry 2007 Oct;62(10):878-83.
72. Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. Journal of Pharmacological Sciences 2015 Jan;127(1):6-9.
73. Cobos EJ, Entrena JM, Nieto FR, Cendán CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Current Neuropharmacology 2008 Dec;6(4):344-66.
74. Hallifax D, Houston JB. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metabolism and Disposition 2007 Aug;35(8):1325-32.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]